Menu
ÚHKT

Impaktované publikace

[21]

Brodska, H.; Drabek, T.; Malickova, K.; Kazda, A.; Vitek, A.; Zima, T.; Markova, M.

Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis : a prospective study

[rok vydání 2009, impact factor 4.931]

[22]

de Witte, T.; Brand, R.; van Biezen, A.; Mufti, G.; Ruutu, T.; Finke, J.; von dem Borne, P.; Vitek, A.; Delforge, M.; Alessandrino, P.; Harlahakis, N.; Russell, N.; Martino, R.; Verdonck, L.; Kröger, N.; Niederwieser, D.

Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors : delay of the transplant is associated with inferior survival.

[rok vydání 2010, impact factor 4.597]

[23]

Robin, M.; Porcher, R.; Zinke-Cerwenka, W.; van Biezen, A.; Volin, L.; Mufti, G.; Craddock, C.; Finke, J.; Richard, C.; Passweg, J.; Peniket, A.; Maertens, J.; Sucak, G.; Gedde-Dahl, T.; Vitek, A.; Nagler, A.; Blaise, D.; Beelen, D.; Maillard, N.; Schwerdtfeger, R.; de Witte, T.; Kroger, N.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: A retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

[rok vydání 2017, impact factor 4.497 ]

[24]

Schetelig, J.; de Wreede, L.C.; van Gelder, M.; Andersen, N.S.; Moreno, C.; Vitek, A.; et al.

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation

[rok vydání 2017, impact factor 4.497 ]

[25]

van Gelder, M.; de Wreede, L.C.; Bornhäuser, M.; Niederwieser, D.; Karas, M.; Anderson, N.S.; Gramatzki, M.; Dreger, P.; Michallet, M.; Petersen, E.; Bunjes, D.; Potter, M.; Beelen, D.; Cornelissen, J.J.; Yakoub-Agha, I.; Russell, N.H.; Finke, J.; Schoemans, H.; Vitek, A.; et al.

Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

[rok vydání 2017, impact factor 4.497 ]

[26]

Koenecke, C.; Heim, D.; van Biezen, A.; Heuser, M.; Aljurf, M.; Kyrcz-Krzemien, S.; Volin, L.; de Souza, C.A.; Gedde-Dahl, T.; Sengeloev, H.; Schanz, U.; Komarnicki, M.; Arroyo, C.H.; Tholouli; E.; Gluckman, E.; Esquirol, A.; Yakoub-Agha, I.; Gürman, G.; Olavarria, E.; Kröger, N.; Rovira, M.; Kahls, P.; Alegre, A.; Nemet, D.; Stamatovic, D.; Vítek, A.; et. al.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy: a report from the EBMT chronic malignancies working party

[rok vydání 2017, impact factor 3.874 ]

[27]

Raj, K.; Eikema, D.-J.; McLornan, D.P.; Olavarria, E.; Blok, H.-J.; Bregante, S.; Ciceri, F.; Passweg, J.; Ljungman, P.; Schaap, N.; Carlson, K.; Zuckerman, T.; de Wreede, L.C.; Volin, L.; Koc, Y.; Diez-Martin, J.L.; Brossart, P.; Wolf, D.; Blaise, D.; Bartolomeo, P.D.; Vitek, A.; et al.

Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the chronic malignancies working party of European society for blood and marrow transplantation

[rok vydání 2019, impact factor 3.853 ]

[28]

McLornan, D.; Szydlo, R.; Koster, L.; Chalandon, Y.; Robin, M.; Wolschke, C.; Beelen, D.; Socié, G.; Bornhäuser, M.; Angelucci, E.; Niederwieser, D.; Gerbitz, A.; Finke, J.; Vitek, A.; et al.

Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European society for blood and marrow transplantation

[rok vydání 2019, impact factor 3.853 ]

[29]

Andersen, N.S.; Bornhäuser, M.; Gramatzki, M.; Dreger, P.; Vitek, A.; et al.

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning

[rok vydání 2019, impact factor 3.656 ]

[30]

Valkova, V.; Vydra, J.; Markova, M.; Cerovska, E.; Vrana, M.; Marinov, I.; Cechova, H.; Cetkovsky, P.; Vitek, A.; Salek, C.

WT1 gene expression in peripheral blood before and after allogeneic stem cell transplantation is a clinically relevant prognostic marker in AML: a single-center 14-year experience

[rok vydání 2020, impact factor 3.231 ]

[31]

Cremers, E.M.; van Biezen, A.; de Wreede, L.; Scholten, M.; Vitek, A.; Finke, J.; Platzbecker, U.; Beelen, D.; Schwerdtfeger, R.; Volin, L.; Harhalakis, N.; Blijlevens, N.; Nagler, A.; Kröger, N.; de Witte, T.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

[rok vydání 2016, impact factor 3.083 ]

[32]

Giebel, S.; Labopin, M.; Holowiecki, J.; Labar, B.; Komarnicki, M.; Koza, V.; Masszi, T.; Mistrik, M.; Lange, A.; Hellmann, A.; Vitek, A.; Pretnar, J.; Mayer, J.; Rzepecki, P.; Indrak, K.; Wiktor-Jedrzejczak, W.; Wojnar, J.; Krawczyk-Kulis, M.; Kyrcz-Krzemien, S.; Rocha, V.

Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers : better results in recent years

[rok vydání 2009, impact factor 2.919]

[33]

Pohlreich, D.; Vitek, A.; Maalouf, J.; Cetkovsky, P.

Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens

[rok vydání 2007, impact factor 2.621]

[34]

Pumannova, M.; Roubalova, K.; Vitek, A.; Sajdova, J.

Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation

[rok vydání 2007, impact factor 2.553]

[35]

Marková, J.; Michková, P.; Burčková, K.; Březinová, J.; Michalová, K.; Dohnalová, A.; Soukupová Maaloufová, J.; Soukup, P.; Vítek, A.; Cetkovský, P.; Schwarz, J.

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

[rok vydání 2011, impact factor 2.548 ]

[36]

Válková, V.; Schwarz, J.; Vítek, A.; Marková, M.; Pohlreich, D.; Benešová, K.; Michalová, K.; Cetkovský, P.; Trněný, M.

The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis

[rok vydání 2010, impact factor 2.475]

[37]

Moravcová, J.; Nádvorníková, S.; Zmeková, V.; Michalová, K.; Březinová, J.; Lukášová, M.; Vítek, A.; Hrabánek, J.; Gašová, Z.; Sedláček, P.; Starý, J.

Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML

[rok vydání 2006, impact factor 2.333]

[38]

van Gelder, M.; Ziagkos, D.; de Wreede, L.; van Biezen, A.; Dreger, P.; Gramatzki, M.; Stelljes, M.; Andersen, N.S.; Schaap, N.; Vitek, A.; et al.

Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia: a retrospective analysis from the chronic malignancies working party of the EBMT

[rok vydání 2017, impact factor 2.308 ]

[39]

Vydra, J.; Válková, V.; Čemusová, B.; Kolář, M.; Nováková, L.; Soukup, P.; Šálek, C.; Vraná, M.; Pytlík, R.; Lesný, P.; Vítek, A.; Cetkovský, P.; Marková, M.

Hematopoietic stem cell transplantation from haploidentical donors in aplasia after cladribine/cytarabine chemotherapy for refractory acute myeloid leukemia or myelodysplastic syndrome

[rok vydání 2019, impact factor 2.298 ]

[40]

Dickinson, A.M.; Hromadníková, I.; Sviland, L.; Jackson, G.H.; Taylor, P.R.A.; Vavřinec, J.; Sedláček, P.; Čermáková, M.; Starý, J.; Vítek, A.; Sajdová, J.; Proctor, S.J.

Use of skin explant model for predicting GVHD in HLA-matched bone marrow transplants : effect of GVHD prophylaxis

[rok vydání 2006, impact factor 2.277]